Showing results (1-10 of 28) with videos related to
Sort By:
Pageof 3
Pharmacology & Therapeutics|March 11, 2014
Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter releaseJohn P M FinbergRambam Maimonides Medical Journal|August 3, 2013
Pharmacology of Rasagiline, a New MAO-B Inhibitor Drug for the Treatment of Parkinson's Disease with Neuroprotective PotentialJohn P M FinbergJournal of Neural Transmission (Vienna, Austria : 1996)|November 3, 2018
Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's diseaseJohn P M FinbergNeuropharmacology|August 9, 2003
L-DOPA increases noradrenaline turnover in central and peripheral nervous systemsLior Dayan, John P M FinbergEuropean Journal of Pharmacology|July 23, 2003
Pharmacological comparison between the actions of methamphetamine and 1-aminoindan stereoisomers on sympathetic nervous function in rat vas deferensSofia Glezer, John P M FinbergInternational Review of Neurobiology|October 6, 2011
Selective inhibitors of monoamine oxidase type B and the "cheese effect"John P M Finberg, Ken GillmanFrontiers in Pharmacology|November 3, 2016
Inhibitors of MAO-A and MAO-B in Psychiatry and NeurologyJohn P M Finberg, Jose M RabeyNeuropharmacology|December 31, 2002
Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behavioursJohn P M Finberg, Moussa B H YoudimNeuropharmacology|May 29, 2004
Rasagiline enhances L-DOPA-induced contralateral turning in the unilateral 6-hydroxydopamine-lesioned guinea-pigDavid Moses, Aviva Gross, John P M FinbergNeuropharmacology|February 22, 2005
Characterization of the neuroprotective activity of rasagiline in cerebellar granule cellsDafna Bonneh-Barkay, Noam Ziv, John P M FinbergPageof 3